Caloplax
Generic Name
Caloplax (Fictional Antiplatelet)
Manufacturer
Global Pharma Solutions Inc.
Country
USA
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| caloplax 1 mg tablet | ৳ 14.00 | N/A |
Description
Overview of the medicine
Caloplax 1 mg Tablet is an antiplatelet agent designed to prevent blood clots in patients at risk of cardiovascular events. It works by inhibiting platelet aggregation, thereby reducing the likelihood of thrombotic complications.
Uses & Indications
Dosage
Adults
1 mg once daily with or without food.
Elderly
No dosage adjustment is generally required for elderly patients.
Renal_impairment
No dosage adjustment is required for patients with mild to moderate renal impairment. Use with caution in severe renal impairment.
How to Take
Take the tablet orally, once daily, with or without food. Swallow the tablet whole with water.
Mechanism of Action
Caloplax selectively inhibits the binding of ADP to its platelet receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation. Its action is irreversible for the life of the platelet.
Pharmacokinetics
Onset
Within 2 hours for initial antiplatelet effect; full effect within 3-7 days.
Excretion
Approximately 50% via urine and 48% via feces.
Half life
Approximately 8-10 hours (for active metabolite).
Absorption
Rapidly absorbed after oral administration. Bioavailability approximately 50%.
Metabolism
Extensively metabolized in the liver, primarily by CYP450 enzymes, to an active metabolite and inactive metabolites.
Side Effects
Contraindications
- Active pathological bleeding (e.g., peptic ulcer, intracranial hemorrhage)
- Hypersensitivity to Caloplax or any component of the tablet
- Severe hepatic impairment
Drug Interactions
Warfarin
Increased risk of bleeding due to additive antiplatelet/anticoagulant effects.
SSRIs/SNRIs
Increased risk of bleeding.
NSAIDs (e.g., Ibuprofen)
Increased risk of gastrointestinal bleeding.
CYP450 Inhibitors (e.g., Omeprazole)
May reduce the antiplatelet effect of Caloplax by inhibiting its conversion to the active metabolite.
Storage
Store below 30°C in a dry place, away from direct sunlight and moisture. Keep out of reach of children.
Overdose
Overdose may lead to prolonged bleeding time and subsequent bleeding complications. Management involves supportive measures and consideration of platelet transfusions if severe bleeding occurs. There is no specific antidote.
Pregnancy & Lactation
Pregnancy Category B. Use only if clearly needed. It is not known whether Caloplax is excreted in human milk. Exercise caution when administered to a nursing mother. Consult your doctor.
Side Effects
Contraindications
- Active pathological bleeding (e.g., peptic ulcer, intracranial hemorrhage)
- Hypersensitivity to Caloplax or any component of the tablet
- Severe hepatic impairment
Drug Interactions
Warfarin
Increased risk of bleeding due to additive antiplatelet/anticoagulant effects.
SSRIs/SNRIs
Increased risk of bleeding.
NSAIDs (e.g., Ibuprofen)
Increased risk of gastrointestinal bleeding.
CYP450 Inhibitors (e.g., Omeprazole)
May reduce the antiplatelet effect of Caloplax by inhibiting its conversion to the active metabolite.
Storage
Store below 30°C in a dry place, away from direct sunlight and moisture. Keep out of reach of children.
Overdose
Overdose may lead to prolonged bleeding time and subsequent bleeding complications. Management involves supportive measures and consideration of platelet transfusions if severe bleeding occurs. There is no specific antidote.
Pregnancy & Lactation
Pregnancy Category B. Use only if clearly needed. It is not known whether Caloplax is excreted in human milk. Exercise caution when administered to a nursing mother. Consult your doctor.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
3 years from the date of manufacture
Availability
Pharmacies, Hospitals
Approval Status
Approved (Fictional)
Patent Status
Patented
Clinical Trials
Extensive Phase I, II, and III clinical trials have demonstrated the efficacy and safety of Caloplax in preventing atherothrombotic events in various patient populations.
Lab Monitoring
- Periodic complete blood count (CBC) to monitor platelet levels and hemoglobin.
- Monitor for signs of bleeding.
Doctor Notes
- Assess bleeding risk factors before initiating Caloplax.
- Educate patients on bleeding symptoms and the importance of adherence.
- Consider genetic testing for CYP2C19 in high-risk patients or those with suboptimal response.
Patient Guidelines
- Take Caloplax exactly as prescribed by your doctor.
- Do not stop taking Caloplax without consulting your doctor, even if you feel well, as this may increase your risk of heart attack or stroke.
- Inform your doctor or dentist that you are taking Caloplax before any surgery or dental procedures.
Missed Dose Advice
If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one.
Driving Precautions
Caloplax is not known to affect the ability to drive or operate machinery. However, if you experience dizziness or any other side effects that may impair your concentration, avoid driving.
Lifestyle Advice
- Maintain a healthy diet and regular exercise.
- Avoid smoking.
- Limit alcohol intake.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Caloplax Brand
Other medicines available under the same brand name
